Navigation Links
5X Competitor II (Mouse) from Takara Mirus Bio

Products5X Competitor II (Mouse) from Takara Mirus Bio
Company Takara Mirus Bio
Item 5X Competitor II (Mouse)
Price $258.00
Description Competitors to lower non-specific signal
Info Takara Mirus BioTakara Mirus Bio
510 Charmany Drive
Suite 273
Madison, WI 53719 USA

Call Takara Mirus Bio to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-866-536-4401
Customer Service: (888) 251-6618 or (608) 441-2844
Fax Number: (608) 441-2845
Web Site: http://www.takaramirusbio.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. PR Competitor Assay Green from Invitrogen
2. PolarScreen Androgen Receptor Competitor Assay Kit, Red from Molecular Probes (Invitrogen)
3. PPARGamma-Competitor Assay Kit Green from Invitrogen
4. PolarScreen Progesterone Receptor Competitor Assay Kit, Far Red from Molecular Probes (Invitrogen)
5. PolarScreen Glucocorticoid Receptor Competitor Assay Kit, Far Red from Molecular Probes (Invitrogen)
6. PolarScreen PPARGamma-Competitor Assay Kit, Red from Molecular Probes (Invitrogen)
7. GPDH Assay Kit from Takara Mirus Bio
8. Bgl I from Takara Mirus Bio
9. Mun I (Mfe I) from Takara Mirus Bio
10. BspT107 I (HgiC I, Ban I) from Takara Mirus Bio
11. Acc I from Takara Mirus Bio
...Description: Proteinase K is a highly active and s...ations purified from the fungus T. album. It cleav...up of N-substituted hydrophobic aliphatic and arom...e protease. Proteinase K is useful in purifying hi...
..., high throughput, water bath thermal cycler capab...oplates. This equates to 9,216 reactions per run w...y transfers a basket of plates between three water... are considerably faster than those of peltier blo...
...tidine Dideoxycytidine is a cytidine analog that ...viral activity. Immunogen: Chemical / Small Mol...ficity of the ddC antiserum was determined by calc...ddC analog at the 50% intercept of the respective ...
MSC.12 class II safety cabinet (Type A1) - CE Marked (230V / 50Hz) from Thermo Scientific
Biology Products:
(Date:12/3/2009)Coral reef fish can undergo a personality change in warmer water, according to an intriguing new study suggesting that climate change may make some species more aggressive. , Experiments with two spe
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
(Date:12/2/2009)PHILADELPHIA Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient,s future risk of death, according to published studies. Now, results of a ne
Breaking Biology News(10 mins):Fish with attitude: Some like it hot 2Grooving down the helix 2Grooving down the helix 3Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 1Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 2Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 3Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 4Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 5Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 6Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 7Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 8Hanger Orthopedic Group Inc Reports 240 31 EPS for the Second Quarter 2009 and Raises Full Year EPS Guidance 53000 9CareFusion Form 10 Registration Statement Declared Effective 52998 1CareFusion Form 10 Registration Statement Declared Effective 52998 2CareFusion Form 10 Registration Statement Declared Effective 52998 3CareFusion Form 10 Registration Statement Declared Effective 52998 4Cell Therapeutics Inc Announces Closing of Public Offering of Common Stock and Warrants 52996 1Cell Therapeutics Inc Announces Closing of Public Offering of Common Stock and Warrants 52996 2
...hange(TM) Software Access Local ...g. 13 BIO-key International,Inc. (OTC Bulletin Bo...utions and finger based biometric identification, ...ftware Module and its acceptance by several,agenci...This contract,represents BIO-key,s first with the ...
...on,Intelligence Corporation (OTC Bulletin Board: C...of electronic signature solutions for,business pro...recognized,leader in biometric signature verificat... three and six-month periods ended June 30, 2007. ...iod ended June 30,2007 increased 24% compared to $...
...o Equity, JERICHO, N.Y., Aug. 15 bioMETRX, Inc. ...d supplier of consumer,biometric products, today a... holders of its Series B common stock warrants tha... company by August 25, 2007. The Company notified...t,has elected to pay such holders $0.12 per share,...
Other Biology News:BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution 2BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution 3Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 2Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 3Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 4Communication Intelligence Corporation Reports Second Quarter 2007 Financial Results 5bioMETRX, Inc. Calls Series B Warrants 2
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,("Simcere" or the "Company") (NYSE: SCR ), a leading pharmaceutical company,specializing in the development, manufacturing, a
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
(Date:12/2/2009)HOBOKEN, N.J., Dec. 2 According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy. Diabetic retinopat
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4